281 related articles for article (PubMed ID: 12716265)
1. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder.
Stocchi F; Nordera G; Jokinen RH; Lepola UM; Hewett K; Bryson H; Iyengar MK;
J Clin Psychiatry; 2003 Mar; 64(3):250-8. PubMed ID: 12716265
[TBL] [Abstract][Full Text] [Related]
2. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
Pollack MH; Zaninelli R; Goddard A; McCafferty JP; Bellew KM; Burnham DB; Iyengar MK
J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817
[TBL] [Abstract][Full Text] [Related]
3. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database.
Rickels K; Rynn M; Iyengar M; Duff D
J Clin Psychiatry; 2006 Jan; 67(1):41-7. PubMed ID: 16426087
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.
Liebowitz MR; Stein MB; Tancer M; Carpenter D; Oakes R; Pitts CD
J Clin Psychiatry; 2002 Jan; 63(1):66-74. PubMed ID: 11838629
[TBL] [Abstract][Full Text] [Related]
7. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.
Rickels K; Zaninelli R; McCafferty J; Bellew K; Iyengar M; Sheehan D
Am J Psychiatry; 2003 Apr; 160(4):749-56. PubMed ID: 12668365
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D; Evans DL; Nemeroff CB
J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626
[TBL] [Abstract][Full Text] [Related]
9. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
Liebowitz MR; Gelenberg AJ; Munjack D
Arch Gen Psychiatry; 2005 Feb; 62(2):190-8. PubMed ID: 15699296
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
[TBL] [Abstract][Full Text] [Related]
11. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline.
Ball SG; Kuhn A; Wall D; Shekhar A; Goddard AW
J Clin Psychiatry; 2005 Jan; 66(1):94-9. PubMed ID: 15669894
[TBL] [Abstract][Full Text] [Related]
12. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder.
Bielski RJ; Bose A; Chang CC
Ann Clin Psychiatry; 2005; 17(2):65-9. PubMed ID: 16075658
[TBL] [Abstract][Full Text] [Related]
13. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.
Montgomery SA; Nil R; Dürr-Pal N; Loft H; Boulenger JP
J Clin Psychiatry; 2005 Oct; 66(10):1270-8. PubMed ID: 16259540
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy for anxiety and comorbid alcohol use disorders.
Ipser JC; Wilson D; Akindipe TO; Sager C; Stein DJ
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007505. PubMed ID: 25601826
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group.
Ravindran AV; Judge R; Hunter BN; Bray J; Morton NH
J Clin Psychiatry; 1997 Mar; 58(3):112-8. PubMed ID: 9108813
[TBL] [Abstract][Full Text] [Related]
16. Remission rates in patients with anxiety disorders treated with paroxetine.
Ballenger JC
J Clin Psychiatry; 2004 Dec; 65(12):1696-707. PubMed ID: 15641876
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.
Sheehan DV; Burnham DB; Iyengar MK; Perera P;
J Clin Psychiatry; 2005 Jan; 66(1):34-40. PubMed ID: 15669886
[TBL] [Abstract][Full Text] [Related]
18. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder.
Wagner KD; Berard R; Stein MB; Wetherhold E; Carpenter DJ; Perera P; Gee M; Davy K; Machin A
Arch Gen Psychiatry; 2004 Nov; 61(11):1153-62. PubMed ID: 15520363
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
Yu YM; Gao KR; Yu H; Shen YF; Li HF
J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
